secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0000950170-24-052052
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx Q1 2024 revenue $109M (+8% YoY); net loss $171M; reaffirms guidance; pipeline advances
--------------------------------------------------------------------------------

- Q1 total revenue $109M (+8% YoY); Crysvita $83M (+9%), Dojolvi $16M (+14%).
- Net loss $171M ($2.03 per share) vs $164M ($2.33) in Q1 2023; operating expenses $274M.
- Reaffirmed 2024 guidance: total revenue $500-530M, Crysvita $375-400M, Dojolvi $75-80M, cash use <$400M.
- Positive interim Phase 1/2 GTX-102 data for Angelman syndrome; OI Phase 3 enrollment complete; DTX401 data expected Q2 2024.
- Cash and equivalents $569M as of March 31, 2024; net cash used in operations $191M in Q1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000095017024052052/0000950170-24-052052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000095017024052052/rare-20240502.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-052052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer